Zelira Therapeutics Ltd (OTCMKTS:ZLDAF) Validates ZTL-101 Medicinal Cannabis Treatment For Chronic Insomnia
Zelira Therapeutics Ltd (OTCMKTS:ZLDAF) has validated its ZTL-101 medicinal cannabis treatment for chronic insomnia. According to the first receipt received from the worldwide clinical trial, the drug is safe and offers effective treatment for insomnia. It allows the company to introduce and distribute ZTL-101 in international markets that comprise the US in H2 2020.
Professor Peter Eastwood led the trial of ZTL-101
Zelira has conducted the clinical trial of ZTL-101 under the leadership of Professor Peter Eastwood at the University of Western Australia Centre for Sleep Science. The team has used the double-blind, randomized, and cross-over design for evaluating the efficacy of ZTL-101, a proprietary cannabis formulation of Zelira, to cure patients who have chronic insomnia.
Clinical trial on 23 patients
The trial is conducted on 23 patients for 14 nights with placebo and 14 nights with ZTL-101 with a one week separation period. After commencing the dosing, each patient can consume a single or double dosage of the medication based on the symptoms.
Managing Director of Zelira USA, Dr. Oludare Odumosu, said the company is excited with the results of the ZTL-101 trial. It has collected vital data necessary for supporting its plans to introduce the clinically validated CBD based insomnia medicine worldwide in 2020. Oludare praised the team at the University of Western Australia Centre for their dedicated efforts for conducting the trial successfully. He also thanked the patients and the participated investigators.
Commenting on the trial, Oludare said it is the most rigorous study conducted ever to ascertain the potential of medical cannabis products to cure chronic insomnia symptoms. He is pleased that ZTL-101 has demonstrated impressive and significant improvements across a variety of insomnia indices.
According to the study, the patients, who are administered the drug, have enjoyed a long and sound sleep during the trial. They again slept immediately after waking up. The benefits observed during the trial include less fatigue, pleasure after sleep, and enhance overall functioning.
70 million people in the US suffer from insomnia
According to the estimates, seventy million people in the US have insomnia. The market for OTC and prescription medications expects to reach $4 billion by the year 2022.
Published at Thu, 07 May 2020 12:01:25 +0000